KRAS and cancer: Macropinocytosis could also play a role in targeting KRAS-mutated cancers and has shown mechanistic differences in macropinocytosis in allele KRAS G12R, where impaired activation of the effector p110alpha PI3K occurs, exposing potential therapeutic vulnerabilities [180].